In preclinical and acute experimental studies, highly selective peptide antagonists targeting ETA (including BQ123 and TAK-044) as well as ETB (BQ788), along with three nonpeptide antagonists (bosentan, macitentan, and ambrisentan), which either exhibit hybrid ETA/ETB antagonist properties or demonstrate ETA selectivity, have been clinically approved for use primarily in the treatment of pulmonary hypertension (Maguire and Davenport, 2015; Bonvallet et al., 1993; Watanabe et al., 1995; Mazzotta et al., 2023). Here, EDNRB is linked to pulmonary arterial hypertension.